Arbutus Biopharma's CFO David Hastings sells shares worth $72,826
David C. Hastings, the Chief Financial Officer of Arbutus Biopharma Corp (NASDAQ:ABUS), recently sold 22,183 common shares of ...
Business Insider1mon
Positive Outlook for Arbutus Biopharma: Promising Developments and Financial Strength Justify Buy Rating
Arbutus Biopharma (ABUS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed Arce from H.C. Wainwright maintained a Buy rating on the stock ...
ETF Daily News1mon
Arbutus Biopharma (NASDAQ:ABUS) Earns Buy Rating from HC Wainwright
Arbutus Biopharma stock opened at $3.21 on Tuesday. The business has a fifty day moving average price of $3.41 and a 200-day moving average price of $3.72. The stock has a market capitalization of ...
Finanznachrichten1mon
Arbutus Biopharma Corporation: Arbutus Provides 2025 Corporate and Financial Update
Jan. 13, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise ...
SG Americas Securities LLC Raises Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS)
SG Americas Securities LLC grew its stake in shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 30.7% during the fourth quarter, Holdings Channel reports. The institutional investor owned ...